FXR1 and cancer: The ROC’s AUC surpassed 0.7 in 9 cancers, indicating FXR1’s high diagnostic efficacy in these cancer types, including CHOL, COAD, ESCA, HNSC, LIHC, LUAD, LUSC, PCPG, and STAD.